Veradermics MANE
NYSE MANE
$148.63 +4.88 (+3.39%)
At close: Nov 10, 2026 · 4:00 PM EST

Veradermics (MANE) Return on Equity [ROE] (2026)

Updated

Veradermics (MANE) posted Return on Equity [ROE] of -13.08% for Q2 2026.

Analysis

Veradermics (MANE) Return on Equity [ROE] (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 19.33%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.63%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 21.60%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 72.13%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -31.17%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.66%
10 Veradermics 822.06 Mn -1.33 Bn - -12.00%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -12.00%
Jun 30, 2026 -15.54%
Mar 31, 2026 -63.31%
API Access

Veradermics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=MANE&period=max&api_key=YOUR_API_KEY